Kessler: FDA pre-emption is of no benefit to public

Share this article:
FDA pre-emption of “failure-to-warn” state lawsuits over drug risks does nothing to benefit the agency or the public and can prevent information that is helpful to the FDA, healthcare providers, and consumers from coming out, say commissioner David Kessler and Georgetown Law professor David Vladeck in the Georgetown Law Journal

While there has been a “steady stream” of such cases against drug companies brought by consumers injured by FDA-regulated drugs, the FDA has stayed on the sidelines, they report, and courts have decided them under the ordinary rules that govern state damages actions, with the question of preemption rarely, if ever, arising.

But Kessler and Vladeck say there are both legal and practical problems with the FDA's new position. They say the FDA's pro-pre-emption arguments are based on a reading of the Federal Food, Drug, and Cosmetic Act that, in their view, understates the ability of manufacturers to change labeling unilaterally to respond to newly discovered risks or to seek labeling changes from the FDA. 
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Is your marketing strategy stuck in 2005?

Is your marketing strategy stuck in 2005?

It is not enough to just have a killer black book or Rolodex. The market needs agile, swift marketing

Is guidance stifling social media?

Recent FDA draft guidance was meant to help companies create FDA-compliant tweets and handle third-party misinformation on the web. What other obstacles lie in the path of effective social media use?

FDA social media guides draw flak

FDA social media guides draw flak

Two FDA guidance documents on how health product manufacturers may participate in social media have drawn criticism from industry and consumer groups.